Marking Shift in Company Strategy, Sigma-Aldrich Teams With BU, NHLBI on Biomarker Validation
August 06, 2010
Marking Shift in Company Strategy, Sigma-Aldrich Teams With BU, NHLBI on Biomarker Validation
The five-year collaboration looking at protein biomarkers associated with atherosclerotic cardiovascular disease stems from the company's desire to "participate more closely in discovery projects," said an official.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Proteomics to Play Important Role in Ten-Year U Penn-Led Study to Predict NSAID Risk and Response
August 10, 2012 / ProteoMonitor - NIH to Provide Access to Exome Sequencing for Mendelian Diseases
August 19, 2011 / GenomeWeb Daily News - 26,000-Patient Study Suggests Triple-Biomarker Approach Could Improve CKD Diagnosis
April 29, 2011 / ProteoMonitor - Funding Update
August 26, 2011 / ProteoMonitor - Movers & Shakers
August 5, 2011 / ProteoMonitor